Treatment of secondary hyperparathyroidism in dialysis: Report of a case-study of treatment failure;Traitement de l'hyperparathyroïdisme secondaire en dialyse : à propos d'un cas d'inefficacité apparente du traitement médicamenteux

Nephrologie et Therapeutique

Volumn 4, Issue 1, 2008, Pages 28-33

  Pruijm, Menno T ^a   Teta, Daniel ^a   Wuerzner, Grégoire ^a   Santschi, Valérie ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cinacalcet; Compliance; Electronic drug monitoring; Medical treatment; Parathormone; Phosphate binders

Indexed keywords

ALUMINUM HYDROXIDE; CALCIMIMETIC AGENT; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; PHOSPHATE BINDING AGENT;

ADULT; ARTICLE; CASE REPORT; DEVICE; DIALYSIS; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; MEDICATION EVENT MONITORING SYSTEM; MICROELECTROMECHANICAL SYSTEM; PARATHYROIDECTOMY; PRESCRIPTION; SECONDARY HYPERPARATHYROIDISM; SLEEP APNEA SYNDROME; TREATMENT FAILURE;

ADULT; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; RENAL DIALYSIS; TREATMENT REFUSAL;

EID: 39149125434     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2007.10.001     Document Type: Article

References (21)

1. Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., and Port F.K. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12 (2001) 2131-2138
2. Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 8 (2004) 1516-1525
3. Lindberg J.S., Culleton B., Wong G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16 (2005) 800-807
4. Elder G.J. Parathyroidectomy in the calcimimetic era. Nephrology 10 (2005) 511-515
5. Shahapuni I., Monge M., Oprisiu R., et al. Drug insights: renal indications of calcimimetics. Nat Clin Pract Nephrol 2 (2006) 326-336
6. Touam M., Menoyo V., Attaf D., Thebaud H., and Druëke T.B. High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe hyperparathyroidism. Kidney Int 67 (2005) 2065-2068
7. Ando R., Naito S., Inagaki Y., et al. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamine D metabolites. Ther Apher Dial 9 (2005) 16-23
8. Garber M.C., Nau D.P., Erickson S.R., AIkens J.E., and Lawrence J.B. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 42 (2004) 649-652
9. Burnier M., Schneider M.P., Chiolero A., Stubi C.L., and Brunner H.R. Hypertension réfractaire: attitudes et perspectives. Med Hyg 55 (1997) 70-72
10. ®) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 90 (2007) 229-237
11. Burnier M., Santschi V., Favrat B., and Brunner H.R. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens 21 suppl 2 (2003) S37-S42
12. Curtin R.B., Svarstad B.L., and Keller T.H. Hemodialysis patients' noncompliance with oral medications. ANNA J 26 (1999) 307-316
13. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 9 (2003) 155-171
14. Leggat J. Adherence with dialysis: a focus on mortality risk. Semin Dial 18 (2005) 137-141
15. Saran R., Bragg-Gresham J.L., Rayner H.C., et al. Non adherence in hemodialysis: associations with mortality, hospitalisation, and practice patterns in the DOPPS. Kidney Int 64 (2003) 254-262
16. Bame S.I., Petersen N., and Wry B.P. Variation in hemodialysis patient compliance according to demographic caracteristics. Soc Sci Med 37 (1993) 1035-1043
17. Kovac J.A., Patel S.S., Peterson R.A., and Kimmel P.L. Patient satisfaction with care and behavioural compliance in end-stage renal disease patients treated with hemodialysis. Am J Kidney Dis 39 (2002) 1236-1244
18. Burnier M., Schneider M.P., Chiolero A., Stubi C.L., and Brunner H.R. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19 (2001) 335-341
19. Denhaerynck K., Steiger J., Bock A., et al. Prevalence and risk factors of non-adherence with immunosuppressive medication in kidney transplant patients. Am J Transplant 7 (2007) 108-116
20. Curtin R.B., Svarstad B.L., Andress D., Keller T., and Sacksteder P. Differences in older versus younger hemodialysis patients'noncompliance with oral medications. Geriatr Nephrol Urol 7 (1997) 35-44
21. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Ther 23 (2001) 1296-1310